TY - JOUR
T1 - Intra-CSF topotecan in treatment of breast cancer patients with leptomeningeal metastases
AU - Jaeckle, Kurt A.
AU - Dixon, Jesse G.
AU - Anderson, Stephen Keith
AU - Moreno-Aspitia, Alvaro
AU - Colon-Otero, Gerardo
AU - Hebenstreit, Kathy
AU - Patel, Tejal A.
AU - Reddy, Samarth L.
AU - Perez, Edith A.
N1 - Publisher Copyright:
© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd
PY - 2020/11/1
Y1 - 2020/11/1
N2 - Background: There are few treatment options for patients with leptomeningeal metastases (LM). Methods: We report a case series of patients with breast cancer and LM treated with intra-CSF topotecan (TOPO). Outcome was assessed by clinical exam and MRI at baseline, at end of induction (4-5 weeks), then every 3 months; CSF cytology was determined at baseline and with each treatment. Results: Thirty-one women [median age, 58 (37-81); median KPS 60 (40-100)] received treatment. At baseline, 68% had positive CSF cytology, and 90%, leptomeningeal enhancement on MRI. 84% of patients also received focal RT (not during TOPO) and 77% received concomitant systemic hormonal or chemotherapy. Median number of TOPO treatments was 14.5 (range, 3-71); median duration of treatment, 11 weeks (1-176); and median OS, 6.9 months (range, 0.9-48.8). Patients remaining progression-free during 4-6 weeks of induction (81%) had a median OS of 11.5 months (range, 1.8-48.8). Overall neurologic PFS at 6, 12, and 24 months was 39%, 26%, and 6%, respectively. Clearing of CSF malignant cells for >3 consecutive samples occurred in 10/21 (48%) patients with positive CSF cytology at baseline, remaining clear for a median duration of 15.9 months (range, 1.4-34.5). Grade 3 adverse events included headache or vomiting (3pts), T2 hyperintensity surrounding the ventricular catheter (2 pts), and meningitis (2 pts). Conclusions: Intra-CSF TOPO, with focal RT as needed for symptomatic areas of enhancement produced durable clearing of CSF malignant cells in 48% of patients positive at baseline, with promising median PFS and OS.
AB - Background: There are few treatment options for patients with leptomeningeal metastases (LM). Methods: We report a case series of patients with breast cancer and LM treated with intra-CSF topotecan (TOPO). Outcome was assessed by clinical exam and MRI at baseline, at end of induction (4-5 weeks), then every 3 months; CSF cytology was determined at baseline and with each treatment. Results: Thirty-one women [median age, 58 (37-81); median KPS 60 (40-100)] received treatment. At baseline, 68% had positive CSF cytology, and 90%, leptomeningeal enhancement on MRI. 84% of patients also received focal RT (not during TOPO) and 77% received concomitant systemic hormonal or chemotherapy. Median number of TOPO treatments was 14.5 (range, 3-71); median duration of treatment, 11 weeks (1-176); and median OS, 6.9 months (range, 0.9-48.8). Patients remaining progression-free during 4-6 weeks of induction (81%) had a median OS of 11.5 months (range, 1.8-48.8). Overall neurologic PFS at 6, 12, and 24 months was 39%, 26%, and 6%, respectively. Clearing of CSF malignant cells for >3 consecutive samples occurred in 10/21 (48%) patients with positive CSF cytology at baseline, remaining clear for a median duration of 15.9 months (range, 1.4-34.5). Grade 3 adverse events included headache or vomiting (3pts), T2 hyperintensity surrounding the ventricular catheter (2 pts), and meningitis (2 pts). Conclusions: Intra-CSF TOPO, with focal RT as needed for symptomatic areas of enhancement produced durable clearing of CSF malignant cells in 48% of patients positive at baseline, with promising median PFS and OS.
KW - breast cancer
KW - leptomeningeal metastasis
KW - neoplastic meningitis
KW - topotecan
UR - http://www.scopus.com/inward/record.url?scp=85090165752&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090165752&partnerID=8YFLogxK
U2 - 10.1002/cam4.3422
DO - 10.1002/cam4.3422
M3 - Article
C2 - 32885617
AN - SCOPUS:85090165752
SN - 2045-7634
VL - 9
SP - 7935
EP - 7942
JO - Cancer medicine
JF - Cancer medicine
IS - 21
ER -